Annovis Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANVS research report →
Companywww.annovisbio.com
Annovis Bio, Inc. , a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders.
- CEO
- Maria L. Maccecchini
- IPO
- 2020
- Employees
- 8
- HQ
- Malvern, PA, US
Price Chart
Valuation
- Market Cap
- $40.13M
- P/E
- -1.39
- P/S
- 0.00
- P/B
- 18.17
- EV/EBITDA
- -0.63
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -318.08%
- ROIC
- -1199.65%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-28,854,197 · -17.34%
- EPS
- $-1.40 · 99.93%
- Op Income
- $-29,695,258
- FCF YoY
- -17.01%
Performance & Tape
- 52W High
- $5.50
- 52W Low
- $1.54
- 50D MA
- $2.15
- 200D MA
- $2.64
- Beta
- 1.26
- Avg Volume
- 867.05K
Get TickerSpark's AI analysis on ANVS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 2, 26 | Hoffman Michael B | buy | 713,800 |
| Dec 8, 25 | Hoffman Michael B | buy | 15,000 |
| Dec 8, 25 | Hoffman Michael B | buy | 30,000 |
| Nov 24, 25 | Hoffman Michael B | buy | 28,096 |
| Nov 24, 25 | Hoffman Michael B | buy | 415 |
| Nov 24, 25 | Hoffman Michael B | buy | 9,200 |
| Nov 24, 25 | Hoffman Michael B | buy | 1,489 |
| Nov 24, 25 | Hoffman Michael B | buy | 28,096 |
| Nov 24, 25 | Hoffman Michael B | buy | 415 |
| Nov 24, 25 | Hoffman Michael B | buy | 9,200 |
Our ANVS Coverage
We haven't published any research on ANVS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ANVS Report →